Literature DB >> 10933061

Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.

E Barbera-Guillem1, K F May, J K Nyhus, M B Nelson.   

Abstract

We investigated the potential role of anti-tumor antibodies and tumor antigens in the formation of immune complexes which promote matrix degradation and angiogenesis. B-cell deficient or B-cell depleted mice showed a reduction in tumor invasion and metastasis. In vitro invasion assays and in vivo models of metastasis showed that anti-sTn antibodies and sTn tumor antigens form complexes which induce granulocytes and macrophages together to mediate tumor invasion and metastasis by processes including extracellular matrix degradation and angiogenesis. These results suggest the existence of a tumor promoting role of a B-cell immune response induced by shed tumor associated antigens of solid, nonlymphoid tumors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10933061      PMCID: PMC1508114          DOI: 10.1038/sj.neo.7900054

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  42 in total

Review 1.  Oncogenic proteins as tumor antigens.

Authors:  M L Disis; M A Cheever
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

Review 2.  Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions.

Authors:  H Ohtani
Journal:  Pathol Int       Date:  1998-01       Impact factor: 2.534

3.  Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis.

Authors:  Y Sugiura; H Shimada; R C Seeger; W E Laug; Y A DeClerck
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

4.  B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses.

Authors:  D A Rowley; R M Stach
Journal:  Int Immunol       Date:  1998-03       Impact factor: 4.823

5.  B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state.

Authors:  R Wijesuriya; S Maruo; J P Zou; M Ogawa; K Umehara; M Yamashita; S Ono; H Fujiwara; T Hamaoka
Journal:  Int Immunol       Date:  1998-08       Impact factor: 4.823

6.  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

Authors:  H O Sjögren; I Hellström; S C Bansal; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

7.  First results for resetting the antitumor immune response by immune corrective surgery in colon cancer.

Authors:  E Barbera-Guillem; M W Arnold; M B Nelson; E W Martin
Journal:  Am J Surg       Date:  1998-10       Impact factor: 2.565

8.  Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.

Authors:  I B Joseph; J T Isaacs
Journal:  J Natl Cancer Inst       Date:  1998-11-04       Impact factor: 13.506

9.  The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis.

Authors:  Z M Shao; M Nguyen; M L Alpaugh; J T O'Connell; S H Barsky
Journal:  Exp Cell Res       Date:  1998-06-15       Impact factor: 3.905

10.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Authors:  P Salven; A Lymboussaki; P Heikkilä; H Jääskela-Saari; B Enholm; K Aase; G von Euler; U Eriksson; K Alitalo; H Joensuu
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

View more
  22 in total

Review 1.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

2.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

3.  A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.

Authors:  Nancy J Nesslinger; Alvin Ng; Kwong-Yok Tsang; Theresa Ferrara; Jeffrey Schlom; James L Gulley; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2010-06-18       Impact factor: 12.531

4.  Tumor cells express FcgammaRI which contributes to tumor cell growth and a metastatic phenotype.

Authors:  M B Nelson; J K Nyhus; K I Oravecz-Wilson; E Barbera-Guillem
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

Review 5.  Regulation of the metastatic cell phenotype by sialylated glycans.

Authors:  Matthew J Schultz; Amanda F Swindall; Susan L Bellis
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

6.  Evaluation of humoral immunity in oral cancer patients from a nigerian referral centre.

Authors:  Victor I Akinmoladun; Olatubosun G Arinola; T Elumelu-Kupoluyi; Lucy O Eriba
Journal:  J Maxillofac Oral Surg       Date:  2012-09-25

Review 7.  B cells and their mediators as targets for therapy in solid tumors.

Authors:  Andrew J Gunderson; Lisa M Coussens
Journal:  Exp Cell Res       Date:  2013-03-13       Impact factor: 3.905

Review 8.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.

Authors:  David G DeNardo; Pauline Andreu; Lisa M Coussens
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 9.  Polarized immune responses differentially regulate cancer development.

Authors:  Magnus Johansson; David G Denardo; Lisa M Coussens
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 10.  Cancer systems immunology.

Authors:  Nathan E Reticker-Flynn; Edgar G Engleman
Journal:  Elife       Date:  2020-07-13       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.